tirzepatide ruling january 2025 Zepbound From Eli Lilly and Company Out of Shortage, Into Controversy:
Description
K., Liu, B., Cui, X., & Brown, K
For dulaglutide users, the corresponding follow-up was, on average, 173 days (median 139 days, IQR 73 to 257 days)
What happens
In conclusion, tirzepatide is a highly effective medication for weight loss in clinical trials
Pharmaceutical products carry an expiration date, which represents the date through which the manufacturer guarantees full potency under specified storage conditions
